AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01825902 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Undergo 18F-FLT PET and 18F-FDG PET
Study NCT01825902 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: diffusion-weighted magnetic resonance imaging
Description: Undergo DW-MRI
Study NCT01825902 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00325078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Study NCT01175746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicardipine
Study NCT01175746 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: remifentanil
Description: 0.1-0.5 ugkg/min during hypotensive anesthesia
Study NCT01208129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NAB001
Description: nail lacquer, once daily, 52 weeks
Study NCT02738723 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EP
Description: Etoposide 75mg/m2/iv over 90min through day 1 to day 4 and cisplatin 25mg/m2/iv over 30min through day 1 to day 3, repeat Q 3weeks. Continuous administration to six cycles or to disease progression, unacceptable toxicity or patients' refusal.
Study NCT02828917 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MedJ-01 Ridaforolimus Eluting Coronary Stent System
Study NCT00006226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: Given PO
Study NCT00006226 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01208129 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: nail lacquer, once daily, 52 weeks
Study NCT03246828 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Omission of gliclazide
Description: Participants will stop taking gliclazide for 3 days. Data from the OGTT will be compared with that prior to stopping the medication.
Study NCT00984204 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapy Cool Path Duo
Description: All patients will be treated with Therapy Cool Path Duo Ablation System for the treatment of typical atrial flutter.
Study NCT00581971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: 400mg bid starting 1 week before radiotherapy and taken through radiotherapy.
Study NCT00581971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV, AUC 2.0, weekly for weeks 1 through 7
Study NCT00581971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV 30 mg/m2, weekly for weeks 1 through 7
Study NCT00581971 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: 70.2Gy, at 1.8Gy qd, Monday through Friday
Study NCT03828734 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theta TMS
Description: TMS will be administered at the frequency of each subject's endogenous theta oscillation (4-7Hz)
Study NCT03828734 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alpha TMS
Description: TMS will be administered at the frequency of each subject's endogenous alpha oscillation (8-12 Hz)
Study NCT03828734 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arrhythmic TMS
Description: TMS will be administered arrhythmically; i.e. a sequence of pulses with randomized timing
Study NCT02341261 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Care Counseling
Study NCT02341261 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised Exercise and Counseling
Study NCT04464330 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: This is an observation study, with no intervention
Study NCT04300673 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radio guided surgery (RGS) using Indium-labelled PSMA
Description: Approximately 24hours prior to surgery (PLND) patients receive a radiolabelled PSMA-tracer. During surgery, urologists will use a gamma-probe to detect PSMA-postitive tumour depostitions in pelvic lymph nodes.
Study NCT02392000 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WatchPAT sleep monitor
Description: Self-management of insomnia using a mobile sleep device
Study NCT02392000 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-i Coach mobile app
Description: Self-management of insomnia using a mobile app based on Cognitive Behavioral Therapy for Insomnia
Study NCT03595696 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Core Muscle Strength Training
Description: Targeted weekly workouts consisting of low-impact aerobic exercises and resistance exercises designed to address muscle imbalance common in women who exhibit DRA and to prompt automatic core engagement while performing compound, multi-joint movements.
Study NCT04135027 — intervention group
Intervention type: OTHER
Intervention: no interventions
Description: no interventions
Study NCT04132778 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AsthmaTuner
Description: Conventional treatment was defined as non-digital self-management using paper individual treatment plans, which contained treatment adjustments of prescribed medications according to symptoms of controlled, partly controlled or uncontrolled asthma, along with instructions according to national guidelines.
Study NCT00842595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 6 courses every 28 days
Study NCT00842595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine
Description: 6 courses every 28 days
Study NCT00842595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: 6 courses every 28 days
Study NCT00842595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: 6 courses every 28 days
Study NCT00842595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 6 courses every 28 days
Study NCT00538083 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chocolate
Description: 22 grams of sugared cocoa, sugar-free cocoa, \& placebo given for six weeks
Study NCT02970240 — intervention group
Intervention type: PROCEDURE
Intervention: Cardiopulmonary testing
Description: A 2-day consecutive testing on an ergometer cycle
Study NCT02865356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine 5% solution
Description: topical solution
Study NCT02865356 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: topical vehicle solution
Study NCT00726843 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 8 weeks of Iyengar Yoga
Description: Participants will attend 8 weekly, 75 min. yoga sessions, followed by 8 weeks of follow-up (will provide headache frequency/intensity)
Study NCT00726843 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 8 weeks of Iyengar Yoga
Description: Participants will provide headache frequency/intensity for 8 weeks, followed by 8 weekly, 75 min. yoga sessions
Study NCT04276558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Udonitrectag
Description: Eye drop solution in single dose unit.
Study NCT01985347 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: Continuous positive airway pressure( CPAP)
Study NCT04276558 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: Eye drop solution with no active substance in single dose unit.
Study NCT04276558 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Eye drop solution with no active substance in single dose unit.
Study NCT03595696 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core Muscle Strength Training
Description: Targeted weekly workouts consisting of low-impact aerobic exercises and resistance exercises designed to address muscle imbalance common in women who exhibit DRA and to prompt automatic core engagement while performing compound, multi-joint movements.
Study NCT02151344 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H7N9 A/Anhui/13 ca influenza virus vaccine
Description: Participants will receive approximately 10\^7.0 fluorescent focus units (FFU) of the vaccine; the vaccine will be administered with a nose spray device.
Study NCT04441970 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neutral position
Description: The cuff pressure will be recorded at the neutral head position.
Study NCT04441970 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Head extension position
Description: The cuff pressure will be recorded at the head extension position.
Study NCT04441970 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Head flexion position
Description: The cuff pressure will be recorded at the head flexion position.
Study NCT02151344 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated subvirion H7N9 vaccine
Description: Participants will receive a dose of 30 mcg of the vaccine; the vaccine will be administered as an injection.
Study NCT02984800 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anesthesia induction
Description: All patients will have inhaled induction of anesthesia by facemask using oxygen and 8% sevoflurane for 2 to 4 minutes followed by placement of an IV cannula. After performing PVB injections, the sevoflurane concentration will be decreased to 0.4% to 0.8% and maintained until completion of surgery.
Study NCT02984800 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PVB injection at L1-L2
Description: Patients will receive a single PVB injection at L1-L2 and placebo PVB injections at T12-L1 and L2-L3.
Study NCT02984800 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PVB injections at T12-L1, L1-L2 and L2-L3.
Description: Patients will have PVB injections at T12-L1, L1-L2 and L2-L3.
Study NCT04788082 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 3D Printed Heart Model
Description: Prior to surgical intervention, the surgeon will be exposed to clinically-indicated images and a patient-specific 3D printed model of the subject's heart anatomy.
Study NCT03320655 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined Aerobic Training
Description: The subjects will perform in ST part, always only 1 set in the 6 machines early mentioned. During the first and second week they will do 12 repetitions at 40% - 50% of 1 RM. In the third and fourth week progress to 10 repetitions at 60%-70% of 1 RM, and in the second and third month, 8 repetitions at 70%-80% of 1 RM. In the AT part the HIIT protocol is based on a ratio 2 min : 1 min. Consisted of 10 interval training periods (2 min of high intensity at 85% - 90% of heart rate reserve (HRreser) and 9 pauses (1 min in passive pause) between interval training periods. During the first week of training will start with a continuous training, in the second week will start with 5 intervals of HIIT, and in the second and third months they are doing the 10 stages of HIIT.
Study NCT03320655 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Combined Strength Training
Description: During the first and second week subjects will perform 1 sets with 12 repetitions at 40% - 50% of 1 RM in the 6 machines mentioned before. In the third and fourth week strength exercises progress to 2 sets of 10 repetitions, at 60%-70% of 1 RM, and in the second and third month consists of 3 sets at 8 repetitions, at 70%-80% of 1 RM. . In the AT part the HIIT protocol is based on a ratio 2 min : 1 min. Consisted of of 5 interval training periods (2 min of high intensity: 85% - 90% of HRreser) and 4 pauses (1 min in passive pause) between interval training periods. During the first week of training will start with a continuous training, in the second week will start with 3 intervals of HIIT, and after the third/fourth week they are doing the 5 stages of HIIT.
Study NCT03455673 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ATE score
Description: The Atrial Thrombus Exclusion (ATE) combine thromboembolic risk factors (hypertension, cardiac insufficiency, history of stoke) and d-dimer level for the prediction of intra-atrial thrombus :~Hypertension = 1 Heart failure = 1 History of stroke = 1 High plasma d-dimer level (> 270 ng/ml) = 1
Study NCT02365623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC207 (bedaquiline)
Description: TMC207 (bedaquiline): Participants will receive TMC207 (bedaquiline) 400 milligram (mg) as 4\*100 mg tablets once daily 2 weeks (14 days) followed by 200 mg (2 tablets) 3 times a week up to Week 24 along with background regimen (BR). Based on the discussion with the Pharmaceuticals and Medical Devices Agency (PMDA), the extension of 24-week TMC207 treatment with BR drugs may occur up to Week 48, under certain circumstances, such that many BR drugs which are susceptible at the beginning of the Treatment Phase show resistance during the Treatment Phase.
Study NCT02365623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Background Regimen (BR)
Description: Participants will receive anti-bacterial tuberculosis drugs (pyrazinamide \[PZA\], ethambutol \[EB, EMB\], streptomycin \[SM\], kanamycin \[KM, KAN\], enviomycin \[EVM\], ethionamide \[TH\], cycloserine \[CS\], para-aminosalicylic acid \[PAS\], amikacin \[AMK\], levofloxacin \[LVFX\] and other fluoroquinolone. Other drugs are used less commonly, such as amoxicillin-clavulanate, linezolid and clofazimine based on Investigator's decision twice a week from Day 1 up to 78 weeks after conversion or 102 weeks after day 1 (what happens first).
Study NCT03283202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avadomide (CC-122)
Description: Avadomide (CC-122) by mouth at the assigned dose in Ph 1 starting on Day 1 for 5 consecutive days per week, followed by 2 days without avadomide (CC-122) administration (5/7) for the first two weeks of a 21-day treatment cycle. If the highest proposed dose level to be explored in Phase 1 is applied, the dosing regimen will be 5/7 days for all 3 weeks of each 21-day treatment cycle.
Study NCT03283202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituxan 375 mg/m2 on Day 1 by intravenous (IV) infusion of a 21-day treatment cycle for up to a total of 6 cycles
Study NCT03283202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 750mg/m2 by IV infusion
Description: Cyclophosphamide 750mg/m2 on Day 1 by IV infusion of a 21-day treatment cycle for up to a total of 6 cycles
Study NCT03283202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine 1.4 mg/m2 (maximum of 2.0 mg total) on Day 1 by IV bolus on Day 1 of a 21-day treatment cycle for up to a total of 6 cycles
Study NCT03283202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 100 mg PO on Days 1 through 5 of each 21-day treatment or 100mg IV on Day 1 is also acceptable for up to a total of 6 cycles
Study NCT03411395 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 5AA+CrPic Water
Description: Dietary supplement drink with carbonation, aroma, amino acids and chromium picolinate
Study NCT03411395 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drink
Description: Placebo water with carbonation and aroma
Study NCT03346330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRK-750
Description: TRK-750 capsule
Study NCT03346330 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule
Study NCT00282126 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Potassium citrate
Description: kcitrate
Study NCT00282126 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Potassium citrate
Description: kcitrate
Study NCT00008385 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study NCT00008385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selenium
Description: Given orally
Study NCT03561233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole 20mg
Description: omeprazole 20 mg twice daily 30 minutes before meal for 4 weeks
Study NCT03244059 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: Belimumab is an anti-BLyS (B-lymphocyte stimulating factor) agent administered by infusion.
Study NCT03244059 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An identically appearing placebo infusion.
Study NCT00582556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zometa
Description: GnRH analogue 3-mo depot - q3 months for 1 yr and Zometa 4 mg IV over 15 min x 1, given 7 days prior to beginning androgen deprivation therapy
Study NCT00582556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zometa
Description: GnRH analogue 3-mo depot - q3 months for 1 yr andZometa 4 mg IV over 15 min x 1, given at mo 6
Study NCT00582556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zometa
Description: GnRH analogue 3-mo depot - q3 months for 1 yr and Zometa 4 mg IV over 15 min, given monthly x 6 months, beginning in month 6.
Study NCT02519114 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Donor Bone Marrow stem cell transplantation
Description: KIR-mismatched haploidentical Bone Marrow stem cell transplantation
Study NCT02590029 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: The 15 minute mindfulness session is a scripted mindfulness exercise that incorporates mindfulness principles of intentionally paying attention to present-moment experience in a non-judgmental fashion.
Study NCT02590029 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Suggestion
Description: The 15 minute suggestion session is a scripted suggestion exercise that incorporates imagery and suggestions for changes in cognition, emotion, and body sensations.
Study NCT02590029 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: The 15 minute psychoeducation session is a supportive session in which behavioral coping strategies for pain management are discussed.
Study NCT03478618 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactated Ringer
Description: Patients will be divided into 2 groups according to the amount of fluids received during caesarian section under spinal anesthesia.~Group (R) 30 patients will receive 15ml/kg/h lactated Ringer (LR) intraoperative. Group (L) 30 patients will receive 30ml/kg/h lactated Ringer (LR) intraoperative. blood loss will be replaced if more than 500 ml in ratio 3 ml crystalloid : 1ml blood in both groups
Study NCT02235506 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: epidural infusion
Description: Lumbar epidural catheter is placed at the L3-4 level using loss-ofresistance procedure. Fentayl 2mcg/ml and 0.2% ropivacaine are infused at a rate of 5ml/hr.
Study NCT02235506 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: femoral sciatic
Description: After femoral and sciatic nerve are identified using ultrasound, 0.2% ropivacaine 20 mL is injected. A catheter is inserted to femoral nerve and 0.2% ropivacaine is infused through the femoral catheter at a rate of 5ml/hr from the end of surgery.
Study NCT02235506 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: epidural infusion
Description: Lumbar epidural catheter is placed at the L3-4 level using loss-ofresistance procedure. Fentayl 2mcg/ml and 0.2% ropivacaine are infused at a rate of 5ml/hr.
Study NCT04441970 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Head rotation position
Description: The cuff pressure will be recorded at the head rotation position.
Study NCT04155281 — intervention group
Intervention type: OTHER
Intervention: urine analysis
Description: New Psychoactive Substances research in urine at admission in unit care
Study NCT01536405 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MMRV (AMP)
Description: Measles, mumps, rubella, and VZV vaccine made with an alternative manufacturing process. Participants will receive two 0.5 mL subcutaneous injections.
Study NCT01536405 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MMRV (2006 process)
Description: Measles, mumps, rubella, and VZV vaccine made with the 2006 manufacturing process. Participants will receive two 0.5 mL subcutaneous injections.
Study NCT01094067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-050089
Description: 5 mg/h intravenously, Tezosentan
Study NCT01094067 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo
Study NCT04165239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KH176
Description: Oral administration of 50 mg KH176 twice daily
Study NCT04165239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KH176
Description: Oral administration of 100 mg KH176 twice daily
Study NCT04165239 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of matching placebo twice daily
Study NCT01484288 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Barostim Neo System
Description: Baroreflex Activation Therapy using the Barostim Neo System
Study NCT01265264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ulodesine
Description: Oral dose administered daily for 84 days.